Publications in collaboration with researchers from University Hospital of Bern (26)

2024

  1. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial

    European Journal of Internal Medicine, Vol. 126, pp. 89-94

  2. Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 7, pp. 890-903

2022

  1. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

    Journal of the American College of Cardiology, Vol. 80, Núm. 13, pp. 1220-1237

  2. Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction

    European heart journal, Vol. 43, Núm. 7, pp. 641-650

2021

  1. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

    Circulation, Vol. 144, Núm. 15, pp. 1196-1211

  2. Dual antiplatelet therapy after PCI in patients at high bleeding risk

    New England Journal of Medicine, Vol. 385, Núm. 18, pp. 1643-1655

  3. Safety and feasibility of mitraclip implantation in patients with acute mitral regurgitation after recent myocardial infarction and severe left ventricle dysfunction

    Journal of Clinical Medicine, Vol. 10, Núm. 9

2020

  1. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data

    EuroIntervention, Vol. 14, Núm. 16, pp. 1451-1457

  2. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study

    Atherosclerosis, Vol. 295, pp. 45-53

  3. Bioresorbable scaffolds versus everolimus-eluting metallic stents: Five-year clinical outcomes of the randomised ABSORB II trial

    EuroIntervention, Vol. 16, Núm. 11, pp. E938-E941

2019

  1. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study

    American Heart Journal, Vol. 209, pp. 97-105

  2. Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?: Insights from the EXAMINATION Trial

    Circulation: Cardiovascular Interventions, Vol. 12, Núm. 9

2018

  1. Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial

    EuroIntervention, Vol. 13, Núm. 16, pp. 1939-1945

  2. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial

    PLoS ONE, Vol. 13, Núm. 8

  3. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

    EuroIntervention, Vol. 13, Núm. 13, pp. 1561-1564

  4. Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial)

    American Journal of Cardiology, Vol. 121, Núm. 9, pp. 1039-1045

  5. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

    EuroIntervention, Vol. 14, Núm. 11, pp. E1224-E1226

  6. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    The Lancet, Vol. 392, Núm. 10151, pp. 940-949

2017

  1. Comparison of everolimus-eluting bioresorbable scaffolds with everolimuseluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial

    Bioresorbable Scaffolds: From Basic Concept to Clinical Applications (CRC Press), pp. 224-237

  2. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy

    JACC: Cardiovascular Interventions, Vol. 10, Núm. 18, pp. 1867-1877